Innovative trifocal (quadrifocal) presbyopia-correcting IOLs: 1-year outcomes from an international multicenter study

PURPOSE: To evaluate visual acuity (VA) and safety of the novel AcrySof IQ PanOptix presbyopia-correcting intraocular lens (IOL) at 12 months post-implantation. SETTING: Seventeen sites in Europe, Australia and South America. DESIGN: Prospective, single-arm, nonmasked, nonrandomized study. METHODS: Of 167 patients enrolled, 149 received study IOLs in both eyes; 145 completed the study. Binocular uncorrected distance VA (UDVA; 4 m), monocular corrected distance VA (CDVA), binocular distance corrected intermediate VA (DCIVA; 60 and 80 cm), binocular uncorrected near VA (UNVA; 40 cm), and binocular defocus curves were evaluated. Safety was assessed by monitoring adverse events (AEs). RESULTS: Of 149 patientss, 62% were women and 93% were white; mean ± SD age was 68.9±9.3 years. At 12 months, mean ± SD binocular UDVA was 0.02±0.11 logarithm of the minimum angle of resolution (logMAR); monocular CDVA was 0.01±0.13 (first eye) and 0.01±0.10 logMAR (second eye); binocular DCIVA was 0.04±0.12 and 0.08±0.14 logMAR at 60 and 80 cm, respectively; and binocular UNVA was 0.07±0.11 logMAR. At 6 months, mean binocular defocus curve VA (0.00 diopter [D] to -3.00 D) ranged from -0.04 to 0.13 logMAR. Binocular VA at distance (0.00 D), intermediate (-1.50 D), and near (-2.50 D) was -0.04±0.11, 0.07±0.13, and 0.07±0.13 logMAR, respectively. Serious ocular AE rates were ≤1.4% in first and second eyes. Posterior capsulotomy rates were 3.4% (first eye) and 2.7% (second eye). CONCLUSIONS: The study IOL provided good VA outcomes. Defocus curve showed VA of 20/25 Snellen or better from near to intermediate distance. Rates of serious and nonserious AEs were low.